SAB Biotherapeutics Plans Sioux Falls Facility

SAB Biotherapeutics will occupy 41,000 sf in University of South Dakota's Discovery District in Sioux Falls. SAB, a clinical-stage biopharmaceutical company, will locate its corporate headquarters, research labs, and a cGMP suite in the 84,000-sf building, which was designed by Perkins+Will and Architecture Incorporated. Alumend, a subsidiary of Avera, will occupy 7,500 sf in the $31 million facility, which will also house the offices of the USD Discovery District and 20,000 sf of leasable space. Groundbreaking is expected in fall of 2018 and completion is expected in 2020. A second 42,000-sf facility will be constructed to accommodate SAB's commercial biomanufacturing production operations.